Novel mediators of FTY720 in human lymphocytes

Transplantation

Volumn 79, Issue 4, 2005, Pages 492-495

  Böhler, Torsten ^a   Budde, Klemens ^a   Neumayer, Hans H ^a   Waiser, Johannes ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

FTY720; Immunosuppression; Transplantation

Indexed keywords

BETA1 INTEGRIN; BETA3 INTEGRIN; CALCINEURIN; CELLULAR APOPTOSIS SUSCEPTIBILITY PROTEIN; COFILIN; FINGOLIMOD; IMMUNOPHILIN; INTEGRIN LINKED KINASE; MICROTUBULE ASSOCIATED PROTEIN 2; MOESIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN UBC9; RAB PROTEIN; RHO FACTOR; SYNTAXIN;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL MOTILITY; CELL VACUOLE; CONTROLLED STUDY; CYTOSKELETON; DRUG MECHANISM; HUMAN; HUMAN CELL; NORMAL HUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL ADHESION; CELL MOVEMENT; CYTOSKELETON; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES; PROPYLENE GLYCOLS; PROTEOMICS; SPHINGOSINE; UBIQUITIN-CONJUGATING ENZYMES;

EID: 14044271525     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000151773.43266.17     Document Type: Article

References (22)

1. Budde K, Schmouder RL, Brunkhorst R, et al. First human trial of FTY, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002; 13: 1073.
2. Yanagawa Y, Sugahara K, Kataoka H, et al. FTY, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J Immunol 1998; 160: 5493.
3. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY targets sphingosine 1-phosphate receptors. J Biol Chem. 2002; 277: 21453.
4. Yopp AC, Fu S, Honig SM, et al. FTY-Enhanced T Cell Homing Is Dependent on CCR2, CCR5, CCR7, and CXCR4: Evidence for Distinct Chemokine Compartments. Immunol 2004; 173: 855.
5. Budde K, Schmouder RL, Nashan B, et al. The pharmacodynamics of single doses of the novel immunosuppressant FTY in stable renal transplant patients. Am J Transplant 2003; 3: 846.
6. Böhler T, Waiser J, Schütz M, et al. FTY induces reversible lymphopenia and changes in the composition of peripheral blood lymphocyte subsets by an apoptosis independent mechanism in human renal allograft recipients: different effects on CD62L+ and CCR5+ T-lymphocyte subpopulations. Transplantation 2004; 77: 1424.
7. Böhler T, Waiser J, Schuetz M, et al. Different effects of FTY on T-lymphocyte subpopulations expressing specific chemokine- and adhesion-receptors. Nephrol Dial Transplant 2004; 3: 702.
8. Billich A, Bornancin F, Devay P, et al. Phosphorylation of the imunomodulatory drug FTY by sphingosine kinases. J Biol Chem 2003; 278: 408.
9. Chen S, Bacon KB, Garcia G, et al. FTY, a novel transplantation drug, modulates lymphocyte migratory responses to chemokines. Transplant Proc 2001 33: 3057.
10. Wang ME, Tejpal N, Qu X, et al. Immunosuppressive effects of FTY alone or in combination with cyclosporine and/or sirolimus. Transplantation 1998; 65: 899.
11. Yuzawa K, Stepkowski S, Wang ME, et al. FTY blocks allograft rejection by sequestration of T and B lymphocytes in peripheral lymphoid compartments. Transplantation 1999; 67: S599.
12. Lan YY, De Crues A, Coates PT, et al. The sphingosine phosphate receptor agonist FTY regulates dendritic cell trafficking by modulation of adehesion molecule expression. Am J Transplant Suppl 2004; 4: 408.
13. Graler MH, Goetzl EJ. The immunosuppressant FTY down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 2004; 18: 551.
14. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296: 346.
15. Seachrist JL, Ferguson SS. Regulation of G protein-coupled receptor endocytosis and trafficking by Rab GTPases. Life Sci 2003; 74: 225.
16. Laporte SA, Miller WE, Kim KM, et al. beta-Arrestin/AP-2 interaction in G protein-coupled receptor internalization: identification of a beta-arrestin binging site in beta 2-adaptin. J Biol Chem 2002; 277: 9247.
17. Teng FY, Wang Y, Tang BL. The syntaxins. Genome Biol 2001; 2: S3012.
18. Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 2001; 53: 1.
19. Muller S, Hoege C, Pyrowolakis G, et al. SUMO, ubiquitin's mysterious cousin. Nat Rev Mol Cell Biol! 2001; 2: 202.
20. Waite KA, Eng C. BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels. Hum Mol Genet 2003; 12: 679.
21. Brinkmann V, Wilt C, Kristofic C, et al. FTY720: dissection of membrane receptor-operated, stereospecific effects on cell migration from receptor-independent antiproliferative and apoptotic effects. Transplant Proc 2001 33:3078.
22. Hale JJ, Yan L, Neway WE, et al. Synthesis, stereochemical determination and biochemical characterization of the enantiomeric phosphate esters of the novel immunosuppressive agent FTY. Bioorg Med Chem 2004 12:4803.